바이오마커 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The global biomarkers market size is expected to reach USD 158.12 Billion in 2034 from USD 63.44 Billion in 2025, growing at a CAGR of 10.68% during 2026-2034.The Global Biomarkers Market is experiencing strong growth due to rising demand for precision medicine and early disease detection. Biomarkers are widely used in diagnostics, drug development, and clinical research to assess disease progression and treatment response. Increasing prevalence of chronic diseases such as cancer and cardiovascular disorders is fueling market expansion.

Key growth drivers include advancements in genomics, proteomics, and molecular diagnostics technologies. Pharmaceutical companies are increasingly utilizing biomarkers in clinical trials to improve drug efficacy and safety. Additionally, growing investments in research and development and collaborations between biotech firms and academic institutions are accelerating innovation.

Looking ahead, the market is expected to benefit from integration with artificial intelligence and big data analytics. Personalized medicine initiatives will further increase demand for biomarker-based testing. Expanding healthcare infrastructure in developing economies will create new opportunities. As diagnostic technologies continue to evolve, the biomarkers market is poised for long-term growth.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Type

• Safety Biomarkers
• Efficacy Biomarkers
• Predictive Biomarkers
• Surrogate Biomarkers
• Pharmacodynamic Biomarkers
• Prognostics Biomarkers
• Validation Biomarkers

By Product

• Consumable
• Services
• Software

By Application

• Diagnostics
• Drug Discovery & Development
• Personalized Medicine
• Disease Risk Assessment
• Others

By Disease

• Cancer
• Cardiovascular Diseases
• Neurological Diseases
• Immunological Diseases
• Others

COMPANIES PROFILED

• F. Hoffmann-La Roche Ltd, Abbott Laboratories, Epigenomics AG, GE HealthCare Technologies Inc., Johnson & Johnson Services Inc., Thermo Fisher Scientific Inc., Bio-Rad Laboratories Inc., Siemens Healthineers AG, QIAGEN N.V., Merck KGaA, PerkinElmer Inc., Agilent Technologies Inc., Eurofins Scientific SE

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL BIOMARKERS MARKET: BY TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Type
• 4.2. Safety Biomarkers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Efficacy Biomarkers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Predictive Biomarkers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Surrogate Biomarkers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Pharmacodynamic Biomarkers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.7. Prognostics Biomarkers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.8. Validation Biomarkers Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL BIOMARKERS MARKET: BY PRODUCT 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Product
• 5.2. Consumable Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Services Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Software Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL BIOMARKERS MARKET: BY APPLICATION 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Application
• 6.2. Diagnostics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Drug Discovery & Development Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Personalized Medicine Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Disease Risk Assessment Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL BIOMARKERS MARKET: BY DISEASE 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Disease
• 7.2. Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Cardiovascular Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Neurological Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.5. Immunological Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL BIOMARKERS MARKET: BY REGION 2022-2034 (USD MN)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.2.1 By Type
  • 8.2.2 By Product
  • 8.2.3 By Application
  • 8.2.4 By Disease
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.3.1 By Type
  • 8.3.2 By Product
  • 8.3.3 By Application
  • 8.3.4 By Disease
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Spain
  • 8.3.10 Russia
  • 8.3.11 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.4.1 By Type
  • 8.4.2 By Product
  • 8.4.3 By Application
  • 8.4.4 By Disease
  • 8.4.5 China
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 India
  • 8.4.9 Australia
  • 8.4.10 South East Asia
  • 8.4.11 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.5.1 By Type
  • 8.5.2 By Product
  • 8.5.3 By Application
  • 8.5.4 By Disease
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.6.1 By Type
  • 8.6.2 By Product
  • 8.6.3 By Application
  • 8.6.4 By Disease
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL BIOMARKERS INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 F. Hoffmann-La Roche Ltd
  • 10.2.2 Abbott Laboratories
  • 10.2.3 Epigenomics AG
  • 10.2.4 GE HealthCare Technologies Inc
  • 10.2.5 Johnson & Johnson Services Inc
  • 10.2.6 Thermo Fisher Scientific Inc
  • 10.2.7 Bio-Rad Laboratories Inc
  • 10.2.8 Siemens Healthineers AG
  • 10.2.9 QIAGEN N.V
  • 10.2.10 Merck KGaA
  • 10.2.11 PerkinElmer Inc
  • 10.2.12 Agilent Technologies Inc
  • 10.2.13 Eurofins Scientific SE